Connective tissue diseases: New cellular players in Sjögren syndrome pathogenesis

Nature Reviews Rheumatology

Volumn 12, Issue 12, 2016, Pages 694-

  Mchugh, Jessica ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BAMINERCEPT;

CD4+ T LYMPHOCYTE; EFFECTOR CELL; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; LYMPHOCYTIC INFILTRATION; NONHUMAN; NOTE; PATHOGENESIS; PD1+ CD4+ T LYMPHOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SJOEGREN SYNDROME; T LYMPHOCYTE SUBPOPULATION; TRANSCRIPTOMICS; CONNECTIVE TISSUE DISEASE;

CONNECTIVE TISSUE DISEASES; HUMANS; SJOGREN'S SYNDROME;

EID: 84992388842     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2016.182     Document Type: Note

References (2)

1. Haskett S., et al. Identification of novel CD4+ T cell subsets in the target tissue of Sjögren's syndrome and their differential regulation by the lymphotoxin/LIGHT signaling axis. J. Immunol. http://dx.doi. org/10.4049/jimmunol.1600407 (2016
2. St Clair E. W., et al. The clinical efficacy and safety of baminercept a lymphotoxin-β receptor fusion protein in primary Sjögren's syndrome: results from a randomized double-blind placebo-controlled phase II trial [abstract]. Arthritis Rheumatol. 67 (Suppl. 10), 3203 (2015